Effect of exercise and strength training on cardiovascular status in HIV-infected patients receiving highly active antiretroviral therapy

AIDS

Volumn 17, Issue SUPPL. 1, 2003, Pages

  Scevola, Daniele ^a   Di Matteo, Angela ^a   Lanzarini, Paolo ^a   Uberti, Filippo ^a   Scevola, Silvia ^a   Bernini, Verginia ^a   Spoladore, Greta ^a   Faga, Angela ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Exercise; Heart disease; Highly active antiretroviral therapy; HIV; Lipodystrophy

Indexed keywords

ANDROGEN; ANTIRETROVIRUS AGENT; ATORVASTATIN; BEZAFIBRATE; CIPROFIBRATE; CLOFIBRATE; CORTICOSTEROID; CYPROHEPTADINE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; GROWTH HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; METFORMIN; MEVINOLIN; NANDROLONE; NICOTINAMIDE; NICOTINIC ACID; OXANDROLONE; PIOGLITAZONE; PRAVASTATIN; PROTEINASE INHIBITOR; ROSIGLITAZONE; SIMVASTATIN; SOMATOMEDIN C; TROGLITAZONE; UNINDEXED DRUG;

AEROBIC CAPACITY; ANAEROBIC CAPACITY; ANTHROPOMETRY; APPETITE; BODY COMPOSITION; BODY FAT; BODY HEIGHT; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHEMICAL ANALYSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; DIET; DIET RESTRICTION; DIET THERAPY; DRUG METABOLISM; DYNAMIC EXERCISE; ENERGY; EVALUATION; EXERCISE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; LABORATORY TEST; LACTATE BLOOD LEVEL; LEAN BODY WEIGHT; LIPID METABOLISM; LIPID STORAGE; LIPOATROPHY; LIPODYSTROPHY; LIVER TOXICITY; MALNUTRITION; METABOLIC DISORDER; METABOLIC RATE; MUSCLE DISEASE; MUSCLE TOXICITY; MYOPATHY; NUTRITIONAL REQUIREMENT; NUTRITIONAL VALUE; OXYGEN CONSUMPTION; PANCREAS FUNCTION; PANCREATITIS; PATIENT COUNSELING; PHYSICAL ACTIVITY; PRESCRIPTION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RHABDOMYOLYSIS; RISK FACTOR; SIDE EFFECT; STRENGTH; TRIACYLGLYCEROL BLOOD LEVEL; WASTING SYNDROME;

EID: 0038204412     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200304001-00015     Document Type: Review

References (54)

1. Palella FJ, Delaney KM, Mooreman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998, 338: 853-860.
2. Dubè MP, Sattler FR: Metabolic complications of antiretroviral therapies. AIDS Clin Care 1998, 10:41-44.
3. Sullivan AK, Nelson MR: Marked hyperlipidaemia on ritonavir. AIDS 1997, 11:938-939.
4. Hengel RL, Watts NB, Lennox JL: Benign symmetric lipomatosis associated with protease inhibitors. Lancet 1997, 350:1596. [Letter]
5. Miller KD, Jones E, Yanovski JA, et al. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 1998, 351:871-875.
6. Carr A, Samaras K, Burton S et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12:F51-F58.
7. Lo JC, Mulligan K, Tai VW, et al. 'Buffalo hump' in men with HIV-infection. Lancet 1998, 351:867-870.
8. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidemia, and insulin resistance. Lancet 1998, 352:1881-1883.
9. Rosenberg HE, Mulder J, Sepkowitz K, et al. 'Protease-paunch' in HIV + persons receiving protease inhibitor therapy: Incidence, risks and endocrinologic evaluation. Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, February 1998 [abstract 408].
10. Kotler DP, Rosenbaum KB, Wang J, et al. Alterations in body fat distribution in HIV-infected men and women. 12th World AIDS Conference. Geneva, June-July 1998 [abstract 32173].
11. Engelson ES, Kotler DP, Tan YX et al. Altered body fat distribution in HIV infection: regional body composition measurements by whole body MRI and DXA scans. 12th World AIDS Conference. Geneva, June-July 1998 [abstract 32181].
12. Boyle BA: Lipodystrophy: A new phenomenon ? AIDS Reader 1999, 9:15-17.
13. Gervasoni C, Ridolfo AL, Trifirò G et al. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS 1999, 13:465-471.
14. Bernasconi E. Metabolic effects of protease inhibitor therapy. AIDS Reader 1999, 9:254-269.
15. Scevola D, Di Matteo A, Uberti F, et al. Reversal of cachexia in patients treated with potent antiretroviral therapy. AIDS Reader 2000, 10:365-375.
16. Henry K, Zackin R, Dube M, et al. Metabolic status and cardiovascular disease risk for a cohort of HIV-1-infected persons durably suppressed on an indinavir-containing regimen (ACTG 372A). Eighth Conference on Retroviruses and Opportunistic Infections. Chicago, February 2001 [abstract 656].
17. Adams PF, Marano MA. Current Estimates From the National Health Interview Survey, 1994. National Center for Health Statistics, Vital and Health Statistics; 1995: series 10, 193. US Department of Health and Human Services, Hyattsville, MD, USA.
18. Department of Health and Human Services. Healthy People 2010, Draft for Public Comment. Department of Health and Human Services, Washington DC, USA, 1999.
19. Henry K, Melroe H, Huebesh J, et al. Experience with the National Cholesterol Education Program (NCEP) guidelines for the identification and treatment of protease inhibitor related lipid abnormalities: results of a prospective study. Sixth Conference on Retroviruses and Opportunistic Infections. Chicago, January-February 1999 [abstract 671].
20. Grunfeld C, Feingold KR. Metabolic disturbances and wasting in the acquired immunodeficiency syndrome. N Engl J Med 1992, 5:329-337.
21. Lonergan JT, Havlir D, Barber E, Mathews WC. Incidence and outcome of hyperlactatemia associated with clinical manifestations in HIV-infected adults receiving NRTI-containing regimens. Eighth Conference on Retroviruses and Opportunistic Infections. Chicago, February 2001 [abstract 624].
22. Scevola D, Bottari G, Oberto L, Faggi A. AIDS cachexia: basics and treatment. In HIV-Infektion, Pathogenese, Diagnostik und Therapie. Edited by Ruf B, Pohle HD, Goebel FD, L'age M. Graefelfing, Germany: Socio-medico Verlag; 1996,: 281-327.
23. Melchior JC, Salmon D, Rigaud D, et al. Resting energy expenditure is increased in stable, malnourished HIV-infected patients. Am J Clin Nutr 1991, 53:437-441.
24. Grunfeld C, Pang M, Shimizu L, et al. Resting energy expenditure, caloric intake and short-term weight change in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Am J Clin Nutr 1992, 55:455-460.
25. Shevitz AH. Resting energy expenditure in the HAART era. AIDS Reader 2000, 10:539-544.
26. World Health Organization. Working group on the use and interpretation of anthropometric indicators of nutritional status. Bull WHO 1986, 64:929-941.
27. Kotler DP, Rosenbaum K, Wang J, Pearson RN. Studies of body composition and fat distribution in HIV-infected and control subjects. J Acquir Immune Defic Syndr Hum Retrovirol 1999, 20:228-237.
28. Scevola D. La cachessia nelle malattie infettive e neoplastiche. Edizioni Medico Scientifiche. EDIMES, Pavia: 1993.
29. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III); 2001 [www.nhlbi.nih.gov/guidelines/cholesterol]. NIH Publication no. 01-3670, Bethesda, MD
30. Dubé MP, Sprecher D, Henry WK et al. Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group. Clin Inf Dis 2000, 31:1216-1224.
31. Von Roenn JH. Management of HIV-related body weight loss. Drugs 1994, 47:774-783.
32. Scevola D, Bottari G, Zambelli A, et al. Trattamento dietetico ed ormonale dei deficit nutrizionali nell'AIDS. Clin Dietol 1992, 19:127-140.
33. Tisdale M, Beck SA. Inhibition of tumour induced lipolysis in vitro and cachexia and tumour growth in vivo by eicosapentaenoic acid. Biochem Pharmacol 1991, 41:103-107.
34. Kardinal CG, Loprinzi CL, Schaid DJ, et al. A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia. Cancer 1990, 65:2657-2662.
35. Scevola D, Zambelli A, Bottari G, et al. Appetite stimulation and body weight gain with medroxyprogesterone acetate in AIDS anorexia and cachexia. Farmaci & Terapia 1991, 3:77-83.
36. Scevola D, Parazzini F, Negri C, Moroni M. Efficacy and safety of high-dose MPA treatment of AIDS cachexia: the italian multicentre study. Fourth Congress of the European Association for Palliative Care. Barcelona, December 1995:443-447 [proceedings].
37. Scevola D, Bottari G, Oberto L et al. A double-blind-placebo controlled trial of megestrol acetate on caloric intake and nutritional status in AIDS cachexia. Fourth Congress of the European Association for Palliative Care. Barcelona, December 1995:427-437 [proceedings].
38. Rondanelli M, Solerte SB, Fioravanti M, et al. Circadian secretory pattern of growth hormone, insulin-like growth factor type I, cortisol, adrenocorticotropic hormone, thyroid-stimulating hormone, and prolactin during HIV infection. AIDS Res Hum Retroviruses 1997, 14:1243-1249.
39. Scevola D, Bottari G, Oberto L, et al. Megestrol acetate (MA) and growth hormone (rHGH) as combined therapy for AIDS cachexia. Fourth Congress of the European Association for Palliative Care. Barcelona, December 1995:438-442 [proceedings].
40. Wanke C, Gerrior J, Kantaros J, et al. Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV. AIDS 1999, 13: 2099-2103.
41. Saint-Marc T, Touraine JL. Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor (PI). Sixth Conference on Retroviruses and Opportunistic Infections. Chicago, January-February 1999 [abstract 672].
42. Walli RK, Michl GM, Bogner JR, et al. Effects of the PPAR-Activator troglitazone on protease inhibitor associated peripheral insulin resistance. Sixth Conference on Retroviruses and Opportunistic Infections. Chicago, January-February 1999 [abstract 673].
43. The Pink Sheet, 27 March 2000, p. 4.
44. Torres R, Unger K. The effect of recombinant human growth hormone on protease-inhibitor-associated fat maldistribution syndrome. Sixth Conference on Retroviruses and opportunistic Infections. Chicago, January-February, 1999 [abstract 675].
45. Strawford A, Barbieri T, Parks E, et al. Resistance exercise and supraphysiologic androgen therapy in eugonadal men with HIV-related weight loss. JAMA 1999, 281:1282-1290.
46. Scevola D, Oberto L, Bottari G, Faggi A. Lipidi e malattie infettive. Congresso Nazionale ADI. Torino, November 1995:187 [abstracts book XII].
47. Scevola D, Bottari G, Oberto L, Faggi A, Venturino P. Problemi nutrizionali del paziente AIDS e strategie terapeutiche. Quaderni Cure Palliative 1996, suppl 1:51-64.
48. Amsterdam EA (editor). Exercise in Cardiovascular Health and Disease. New York: Yorke Medical Books; 1977.
49. Smith BA, Neidig JL, Nickel JT, et al. Aerobic exercise: effects on parameters related to fatigue, dyspnea, weight and body composition in HIV-infected adults. AIDS 2001, 15:693-701.
50. Montoye HJ. Physical Activity and Health: An Epidemiologic Study of an Entire Community. Englewood Cliffs, NJ: Prentice-Hall; 1975.
51. Katch FI, Freedson PS, Jones CA, et al. Evaluation of acute cardiorespiratory responses to hydraulic resistance exercise. Med Sci Sports Exerc 1985, 17:168-173.
52. Crow RS, Rantaharju PM, Prineas RJ, et al. Risk factors, exercise fitness and electrocardiographic response to exercise in 12,866 men at risk of symptomatic coronary heart disease. Am J Cardiol 1986, 57:1075-1082.
53. Pollock M, Gaesser G, Butcher J, et al. The recommended quantity and quality of exercise for developing and maintaining cardiorespiratory and muscular fitness, and flexibility in healthy adults. Med Sci Sports Exerc 1998, 30:975-991.
54. Stringer WW, Berezovskaya M, O'Brien WA, et al. The effect of exercise training on aerobic fitness, immune indices, and quality of life in HIV + patients. Med Sci Sports Exerc 1998, 30:11-16.